Clinical Trial Update: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing M7824 (bintrafusp alfa) to pembrolizumab as first-line treatment in PD-L1-expressing advanced non-small cell lung cancer; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• M7824 (bintrafusp alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-06-29